A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
Condition:   Poliomyelitis Interventions:   Biological: vaccination with novel OPV2 candidate 1 vaccine;   Biological: vaccination with novel OPV2 candidate 2 vaccine;   Biological: Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.)) Sponsors:   Pierre Van Damme;   Bill and Melinda Gates Foundation;   Centers for Disease Control and Prevention;   PATH;   Celerion Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
Conditions:   Covid19;   SARS (Severe Acute Respiratory Syndrome);   SARS-CoV Infection;   SARS-CoV-2 Interventions:   Biological: Biological: oral polio vaccine;   Biological: Comparable Placebo;   Drug: NA-831;   Drug: Comparable Placebo of drug;   Combination Product: Combination of oral polio vaccine and NA-831;   Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of dr ug Sponsors:   NeuroActiva, Inc.;   Biomed Industries, Inc. Enrolling by in...
Source: ClinicalTrials.gov - September 7, 2020 Category: Research Source Type: clinical trials

Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
Condition:   Poliomyelitis Interventions:   Biological: Novel Oral Polio Vaccine Type 1 (nOPV1);   Biological: Novel Oral Polio Vaccine Type 3 (nOPV3);   Biological: Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1);   Biological: Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3) Sponsors:   PATH;   Bill and Melinda Gates Foundation;   Centers for Disease Control and Prevention;   Viroclinics Biosciences B.V.;   The Emmes Company, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 27, 2020 Category: Research Source Type: clinical trials

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents
Condition:   Meningococcal Infection (Healthy Volunteers) Interventions:   Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine;   Biological: Meningococcal group A, C, W-135, and Y conjugate vaccine;   Biological: Human Papillomavirus 9-valent Vaccine 9vHPV;   Biological: Tetanus Toxoid, Red uced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine Tdap-IPV Sponsor:   Sanofi Pasteur, a Sanofi Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 28, 2020 Category: Research Source Type: clinical trials

Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq ® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)
Condition:   Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9 Interventions:   Biological: RotaTeq (V260);   Biological: IPV Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 22, 2020 Category: Research Source Type: clinical trials